DERM - デルミラ (Dermira Inc.) デルミラ

 DERMのチャート


 DERMの企業情報

symbol DERM
会社名 Dermira Inc (デルミラ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 ダーミラ(Dermira Inc.)はバイオ医薬品会社である。同社は乾癬、多汗症、アクネ等の皮膚症状を治療する皮膚病学の治療ソリューションの開発に従事する。同社のポートフォリオはセルトリズマブ・ペゴルのCimzia、グリコピロニウム・トシラート、olumacostat glasaretilという3つの後期製品候補を含む。Cimziaは注射性生物学的腫瘍壊死因子(TNF)アルファ阻害薬であり、リューマチ性関節炎、乾癬性関節炎、強直性せきつい炎、クローン病を含む各種炎症性疾患の治療のために認可・販売される。グリコピロニウム・トシラートは原発性腋窩多汗症の治療向けの局所適用小分子抗コリン作用薬である。olumacostat glasaretilはアクネの治療用局所適用皮脂生成をターゲットとする小分子である。   デルミラは米国のバイオ医薬品会社。皮膚科用製品の開発と製造に注力する。新薬候補には中度・重度の尋常性乾癬症治療用モノクロナ―ル抗体「シムジア(セルトリズマブペゴ―ル)」、多汗症治療用の小分子抗コロン作用薬DRM04、にきび治療用皮脂抑制剤DRM01がある。本社はカリフォルニア州。   Journey is focused on identifying, acquiring and strategically commercializing innovative, differentiated dermatology products through its efficient sales and marketing model. The Journey team is comprised of industry experts with extensive experience commercializing some of the most successful prescription dermatology brands. Journey was formed in 2014 and is a subsidiary of Fortress Biotech, Inc. Journey’s core purpose is to positively impact people’s lives and well-being by providing effective solutions for treating skin conditions, healing wounds and supporting healthy skin.
本社所在地 275 Middlefield Road Suite 150 Menlo Park CA 94025 USA
代表者氏名 Thomas G. Wiggans トーマス・G・ウィガンズ
代表者役職名 Chairman of the Board Chief Executive Officer Co-Founder
電話番号 +1 650-421-7200
設立年月日 40391
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数 162人
url www.dermira.com
nasdaq_url https://www.nasdaq.com/symbol/derm
adr_tso
EBITDA EBITDA(百万ドル) -179.77200
終値(lastsale) 11.92
時価総額(marketcap) 500954568.8
時価総額 時価総額(百万ドル) 508.09910
売上高 売上高(百万ドル) 41.78800
企業価値(EV) 企業価値(EV)(百万ドル) 351.47710
当期純利益 当期純利益(百万ドル) -318.37200
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Dermira Inc revenues increased from $2.1M to $39.4M. Net loss increased 22% to $83.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and Administrative increase from $19M to $61.7M (expense) Interest Expense increase from $1.3M to $9M (expense).

 DERMのテクニカル分析


 DERMのニュース

   Journey Medical Corporation (NASDAQ: DERM): Time To Buy Over The Next Few Months  2022/09/05 12:30:00 Marketing Sentinel
In the last trading session, 50487.0 Journey Medical Corporation (NASDAQ:DERM) shares changed hands as the company’s beta touched 0. With the company’s per share price at $3.03 changed hands at -$0.17 or -5.46% during last session, the market valuation stood at $35.12M. DERM’s last price was a discount, traded about -236.63% off its 52-week high … Journey Medical Corporation (NASDAQ: DERM): Time To Buy Over The Next Few Months Read More »
   Journey Medical Corporation Announces Settlement Agreements Pertaining to QBREXZA, AMZEEQ and ZILXI Patent Exclusivity  2022/05/24 12:30:00 Wallstreet:Online
SCOTTSDALE, Ariz., May 24, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical” or the “Company”), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced that Journey Medical and Padagis US LLC (“Padagis”) entered into a
   Journey Medical Corp Shares Close in on 52-Week Low - Market Mover  2021/12/27 10:37:26 Kwhen Finance
Journey Medical Corp (DERM) shares closed today at 1.4% above its 52 week low of $5.62, giving the company a market cap of $60M. The stock is currently down 40.0% year-to-date, down 40.0% over the past 12 months, and down 40.0% over the past five years. This week, the Dow Jones Industrial Average rose 1.6%, and the S&P 500 rose 2.3%. Trading Activity Trading volume this week was 62.3% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -3669.7% The company's stock price performance over the past 12 months lags the peer average by 883.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Journey Medical Corp Shares Near 52-Week Low - Market Mover  2021/12/26 11:48:15 Kwhen Finance
Journey Medical Corp (DERM) shares closed today at 1.4% above its 52 week low of $5.62, giving the company a market cap of $60M. The stock is currently down 40.0% year-to-date, down 40.0% over the past 12 months, and down 40.0% over the past five years. This week, the Dow Jones Industrial Average rose 1.6%, and the S&P 500 rose 2.3%. Trading Activity Trading volume this week was 61.4% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -3669.7% The company's stock price performance over the past 12 months lags the peer average by 883.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Acne Vulgaris Treatment Market Research Study, Future Prospects and Growth Drivers to 2027 | Top Key Vendors - Common Pharma Inc, Cutanea Life Sciences Inc, Dermira Inc  2021/10/29 10:32:49 OpenPR
The global Acne Vulgaris Treatment market size is projected to a CAGR of 5.7% during 2021-2027. To examine the market''s effect forces and prospective prospects, the research includes an in-depth examination of the competitive landscape, product market size, product benchmarking,
   Journey Medical Corporation Announces Settlement Agreements Pertaining to QBREXZA, AMZEEQ and ZILXI Patent Exclusivity  2022/05/24 12:30:00 Wallstreet:Online
SCOTTSDALE, Ariz., May 24, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical” or the “Company”), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced that Journey Medical and Padagis US LLC (“Padagis”) entered into a
   Journey Medical Corp Shares Close in on 52-Week Low - Market Mover  2021/12/27 10:37:26 Kwhen Finance
Journey Medical Corp (DERM) shares closed today at 1.4% above its 52 week low of $5.62, giving the company a market cap of $60M. The stock is currently down 40.0% year-to-date, down 40.0% over the past 12 months, and down 40.0% over the past five years. This week, the Dow Jones Industrial Average rose 1.6%, and the S&P 500 rose 2.3%. Trading Activity Trading volume this week was 62.3% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -3669.7% The company's stock price performance over the past 12 months lags the peer average by 883.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Journey Medical Corp Shares Near 52-Week Low - Market Mover  2021/12/26 11:48:15 Kwhen Finance
Journey Medical Corp (DERM) shares closed today at 1.4% above its 52 week low of $5.62, giving the company a market cap of $60M. The stock is currently down 40.0% year-to-date, down 40.0% over the past 12 months, and down 40.0% over the past five years. This week, the Dow Jones Industrial Average rose 1.6%, and the S&P 500 rose 2.3%. Trading Activity Trading volume this week was 61.4% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -3669.7% The company's stock price performance over the past 12 months lags the peer average by 883.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Acne Vulgaris Treatment Market Research Study, Future Prospects and Growth Drivers to 2027 | Top Key Vendors - Common Pharma Inc, Cutanea Life Sciences Inc, Dermira Inc  2021/10/29 10:32:49 OpenPR
The global Acne Vulgaris Treatment market size is projected to a CAGR of 5.7% during 2021-2027. To examine the market''s effect forces and prospective prospects, the research includes an in-depth examination of the competitive landscape, product market size, product benchmarking,
   Acne Vulgaris Treatment Market Research Study, Future Prospects and Growth Drivers to 2027 | Top Key Vendors - Common Pharma Inc, Cutanea Life Sciences Inc, Dermira Inc  2021/10/29 10:32:49 OpenPR
The global Acne Vulgaris Treatment market size is projected to a CAGR of 5.7% during 2021-2027. To examine the market''s effect forces and prospective prospects, the research includes an in-depth examination of the competitive landscape, product market size, product benchmarking,

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 デルミラ DERM Dermira Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)